Trial of canakinumab, an IL-1{beta} receptor antagonist, in patients with inclusion body myositis
Conclusions
In this long-term, open-label study, canakinumab showed small, but not clinically appreciable, stabilizing benefits in 2 of 5 patients with sIBM over 1 year, was ineffective in 2 others, and might have worsened one. No patient improved.
Classification of evidence
This study provides Class IV evidence that canakinumab was ineffective for patients with sIBM.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Kosmidis, M. L., Pikazis, D., Vlachoyiannopoulos, P., Tzioufas, A. G., Dalakas, M. C. Tags: All Immunology, Muscle disease, Clinical trials Observational study (Cohort, Case control), Class IV Article Source Type: research
More News: Allergy & Immunology | Brain | Clinical Trials | Inclusion-Body Myositis | Neurology | Study